Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction.
Seven patients with Fabry's disease and severe pain received carbamazepine (CMZ). Five of 7 patients had moderate to complete relief based upon self-assessment of pain levels. Preexisting autonomic dysfunction was exacerbated by CMZ in 2. Complications encountered were ileus, urinary retention, and gastrointestinal disturbance. Although CMZ was useful in treatment of pain, caution should be employed in this disease.
Filling-Katz
M R
MR
Developmental and Metabolic Neurology Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD.
Merrick
H F
HF
Fink
J K
JK
Miles
R B
RB
Sokol
J
J
Barton
N W
NW
D000328:Adult; D000698:Analgesia; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D000795:Fabry Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy
D002220:Carbamazepine